08:00 , Dec 15, 2014 |  BC Week In Review  |  Clinical News

Ciprofloxacin dry powder for inhalation regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation to ciprofloxacin dry powder for inhalation (DPI) from Bayer to treat non-cystic fibrosis bronchiectasis. Ciprofloxacin DPI is in Phase III testing for non-CF bronchiectasis. The DPI formulation...
07:00 , May 5, 2014 |  BC Week In Review  |  Clinical News

Ciprofloxacin dry powder for inhalation regulatory update

FDA granted Orphan Drug designation to Bayer's ciprofloxacin dry powder for inhalation (DPI) to treat non-cystic fibrosis bronchiectasis. Ciprofloxacin DPI is in Phase III testing as a chronic intermittent therapy for reducing the frequency of...